{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:41:56Z","timestamp":1762299716573,"version":"build-2065373602"},"reference-count":38,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Second-generation antipsychotic drugs, such as olanzapine, have been\n                        associated with metabolic side effects including significant weight gain.\n                        Recent evidence suggests that this adverse effect may be attenuated by\n                        metformin.<\/jats:p>\n                  <jats:p>Male Wistar rats were chronically treated with olanzapine, together with or\n                        without metformin, for 7 and 14 weeks. Feeding behavior, food intake, and\n                        weight gain were recorded, as well as plasma leptin and triglyceride levels\n                        were measured. The expression of hypothalamic candidate genes, Pomc\n                        and Npy, involved in appetite and energy balance expressions\u2019 was\n                        assessed by quantitative real-time polymerase chain reaction.<\/jats:p>\n                  <jats:p>Olanzapine alone caused significant body weight gain, and the\n                        co-administration of metformin for 14 weeks lowered body weight and food\n                        intake compared with both the 7-week and control groups. Plasma triglyceride\n                        levels did not differ among groups. Leptin levels were significantly higher\n                        in the olanzapine-only group and were lower in both metformin-olanzapine\n                        groups, more promising in the early co-treatment with metformin. Compared to\n                        the control group, the hypothalamus of the olanzapine treatment group\n                        exhibited downregulated Pomc expression and upregulated Npy\n                        expression.<\/jats:p>\n                  <jats:p>Early co-treatment with metformin significantly mitigated olanzapine-induced\n                        weight gain and food intake, demonstrating its potential in preventing\n                        metabolic side effects when initiated at the beginning of antipsychotic\n                        therapy.<\/jats:p>","DOI":"10.1055\/a-2634-7726","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:59:20Z","timestamp":1752231560000},"page":"285-292","source":"Crossref","is-referenced-by-count":0,"title":["Time-Dependent Effects of Metformin and Olanzapine on the Metabolic\n                    System"],"prefix":"10.1055","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1465-8324","authenticated-orcid":false,"given":"Gizem","family":"Kurt","sequence":"additional","affiliation":[{"name":"Middle East Technical University, Department of Biological Sciences,\n                    Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5710-3068","authenticated-orcid":false,"given":"Seyda T.","family":"Durhan","sequence":"additional","affiliation":[{"name":"Middle East Technical University, Department of Biochemistry, Ankara,\n                    Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7432-4871","authenticated-orcid":false,"given":"Mehmet","family":"Ak","sequence":"additional","affiliation":[{"name":"Necmettin Erbakan University, Meram Faculty of Medicine, Department of\n                    Psychiatry, Konya, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7191-2264","authenticated-orcid":false,"given":"Tulin","family":"Yanik","sequence":"additional","affiliation":[{"name":"Middle East Technical University, Department of Biological Sciences,\n                    Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/J.MOLMED.2010.10.010","article-title":"Antipsychotic drugs and obesity","volume":"17","author":"C U Correll","year":"2011","journal-title":"Trends Mol Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/J.PHARMTHERA.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment--pharmacological\n                    mechanisms","volume":"125","author":"G P Reynolds","year":"2010","journal-title":"Pharmacol Ther"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.9740\/MHC.2022.08.254","article-title":"Opioid antagonists to prevent olanzapine-induced weight gain: A systematic\n                    review","volume":"12","author":"S A Laguado","year":"2022","journal-title":"Ment Health Clin"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"79449","DOI":"10.3389\/FENDO.2014.00058\/BIBTEX","article-title":"Peptides and food intake","volume":"5","author":"C S Crespo","year":"2014","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"257776","DOI":"10.3389\/FENDO.2017.00075\/BIBTEX","article-title":"Regulation of agouti-related protein and pro-opiomelanocortin gene expression in\n                    the avian arcuate nucleus","volume":"8","author":"T Boswell","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1530\/JOE-10-0418","article-title":"POMC overexpression in the ventral tegmental area ameliorates dietary\n                    obesity","volume":"210","author":"L M Andino","year":"2011","journal-title":"J Endocrinol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"E3699","DOI":"10.1210\/CLINEM\/DGAC342","article-title":"Obesity and hyperphagia with increased defective ACTH: A novel POMC variant","volume":"107","author":"E S Van Der Valk","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1126\/sciadv.abm1232","article-title":"Receptor-specific recognition of NPY peptides\n                    revealed by structures of NPY receptors","volume":"8","author":"T Tang","year":"2022","journal-title":"Sci\n                    Adv"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"101455","DOI":"10.1016\/J.MOLMET.2022.101455","article-title":"NPY derived from AGRP neurons controls feeding via Y1 and energy expenditure and\n                    food foraging behaviour via Y2 signalling","volume":"59","author":"Y Qi","year":"2022","journal-title":"Mol Metab"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"994827","DOI":"10.3389\/FNUT.2022.994827\/BIBTEX","article-title":"Fasting inhibits excitatory synaptic input on paraventricular oxytocin neurons\n                    via neuropeptide Y and Y1 receptor, inducing rebound hyperphagia, and weight\n                    gain","volume":"9","author":"L Wang","year":"2022","journal-title":"Front Nutr"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/NRENDO.2013.256","article-title":"Metformin \u2013 mode of action and clinical implications for diabetes and\n                    cancer","volume":"10","author":"I Pernicova","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/IJO.2012.144","article-title":"Pharmacotherapy for childhood obesity: present and future prospects","volume":"37","author":"R Sherafat-Kazemzadeh","year":"2013","journal-title":"Int J Obes (Lond)"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1176\/APPI.AJP.2007.07010079","article-title":"Metformin addition attenuates olanzapine-induced weight gain in drug-naive\n                    first-episode schizophrenia patients: A double-blind, placebo-controlled\n                    study","volume":"165","author":"R R Wu","year":"2008","journal-title":"Am J Psychiatry"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1176\/AJP.2006.163.12.2072","article-title":"A randomized, double-blind, placebo-controlled trial of metformin treatment of\n                    weight gain associated with initiation of atypical antipsychotic therapy in\n                    children and adolescents","volume":"163","author":"D J Klein","year":"2006","journal-title":"Am J Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/J.PNPBP.2013.10.006","article-title":"Antidiabetic-drug combination treatment for glucose intolerance in adult female\n                    rats treated acutely with olanzapine","volume":"48","author":"H N Boyda","year":"2014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1530\/JOE-15-0074","article-title":"Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin\n                    resistance","volume":"227","author":"G J Remington","year":"2015","journal-title":"J Endocrinol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"41085","DOI":"10.1038\/SREP41085","article-title":"Synergistic effects of metformin with liraglutide against endothelial\n                    dysfunction through GLP-1 receptor and PKA signalling pathway","volume":"7","author":"J Ke","year":"2017","journal-title":"Sci Rep"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/J.PNPBP.2016.06.012","article-title":"Dysregulation of hypothalamic modulation in olanzapine treated male rats","volume":"71","author":"D Sezlev-Bilecen","year":"2016","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/J.BRAINRES.2014.10.070","article-title":"Effects of risperidone treatment on the expression of hypothalamic neuropeptide\n                    in appetite regulation in Wistar rats","volume":"1596","author":"C Kursungoz","year":"2015","journal-title":"Brain Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/J.JNEUMETH.2005.02.004","article-title":"Novel oral drug administration in an animal model of neuroleptic therapy","volume":"146","author":"S B Schleimer","year":"2005","journal-title":"J Neurosci Methods"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1373\/CLINCHEM.2008.112797","article-title":"The MIQE guidelines: Minimum information for publication of quantitative\n                    real-time PCR experiments","volume":"55","author":"S A Bustin","year":"2009","journal-title":"Clin Chem"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1017\/S146114571300093X","article-title":"Modelling olanzapine-induced weight gain in rats","volume":"17","author":"E M Van Der Zwaal","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/J.1365-2125.2010.03783.X","article-title":"Metformin for olanzapine-induced weight gain: A systematic review and\n                    meta-analysis","volume":"71","author":"S K Praharaj","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"113049","DOI":"10.1016\/J.BBR.2020.113049","article-title":"Peripheral mechanisms of acute olanzapine induced metabolic dysfunction: A\n                    review of in vivo models and treatment approaches","volume":"400","author":"H Shamshoum","year":"2021","journal-title":"Behav Brain Res"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/SCHBUL\/SBAE205","article-title":"Metformin for the prevention of antipsychotic-induced weight gain: Guideline\n                    development and consensus validation","author":"A Carolan","year":"2024","journal-title":"Schizophr Bull"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3389\/FPSYT.2024.1491417\/PDF","article-title":"Metformin in the management of antipsychotic-induced weight gain \u2013 why the\n                    \u2018weight\u2019?","volume":"15","author":"I Fitzgerald","year":"2024","journal-title":"Front Psychiatry"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/J.PHYSBEH.2011.05.033","article-title":"Atypical antipsychotics and the neural regulation of food intake and peripheral\n                    metabolism","volume":"104","author":"K L Teff","year":"2011","journal-title":"Physiol Behav"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/J.PSYNEUEN.2012.06.012","article-title":"The investigation of leptin and hypothalamic neuropeptides role in first attack\n                    psychotic male patients: Olanzapine monotherapy","volume":"38","author":"M Ak","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/OBY.2010.6","article-title":"Increased food intake and energy expenditure following administration of\n                    olanzapine to healthy men","volume":"18","author":"R J Fountaine","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-activated protein kinase in mechanism of metformin action","volume":"108","author":"G Zhou","year":"2001","journal-title":"J Clin Invest"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"880","DOI":"10.2337\/DB13-0194","article-title":"Metformin lowers plasma triglycerides by promoting VLDL-triglyceride clearance\n                    by brown adipose tissue in mice","volume":"63","author":"J J Geerling","year":"2014","journal-title":"Diabetes"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"999","DOI":"10.2217\/PGS.11.45","article-title":"Pharmacogenetics of leptin in antipsychotic-associated weight gain and\n                    obesity-related complications","volume":"12","author":"A K Lee","year":"2011","journal-title":"Pharmacogenomics"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/J.SCHRES.2007.11.026","article-title":"Impact of atypical antipsychotic therapy on leptin, ghrelin, and\n                    adiponectin","volume":"100","author":"H Jin","year":"2008","journal-title":"Schizophr Res"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1590\/S1516-44462012000200009","article-title":"Energy metabolism, leptin, and biochemical parameters are altered in rats\n                    subjected to the chronic administration of olanzapine","volume":"34","author":"A I Zugno","year":"2012","journal-title":"Revista Brasileira de Psiquiatria"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/J.NPEP.2006.01.002","article-title":"Neuropeptide Y mRNA expression levels following chronic olanzapine, clozapine\n                    and haloperidol administration in rats","volume":"40","author":"X F Huang","year":"2006","journal-title":"Neuropeptides"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"5061","DOI":"10.1172\/JCI70338","article-title":"Serotonin 2C receptors in pro-opiomelanocortin neurons regulate energy and\n                    glucose homeostasis","volume":"123","author":"E D Berglund","year":"2013","journal-title":"J Clin Invest"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/374542A0","article-title":"Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors","volume":"374","author":"L H Tecott","year":"1995","journal-title":"Nature"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"293","DOI":"10.5483\/BMBREP.2022.55.6.026","article-title":"Metformin ameliorates olanzapine-induced disturbances in POMC neuron number,\n                    axonal projection, and hypothalamic leptin resistance","volume":"55","author":"J Kim","year":"2022","journal-title":"BMB Rep"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2634-7726.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:35:45Z","timestamp":1762299345000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2634-7726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":38,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2025,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2634-7726","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"type":"print","value":"0176-3679"},{"type":"electronic","value":"1439-0795"}],"subject":[],"published":{"date-parts":[[2025,7,10]]}}}